Timothy G. Rothwell has been the Chairman of Emisphere Technologies Inc. (OTC: EMIS), since early 2012 and prior to that a Director of the Company from late 2009. Mr. Rothwell is also the Chairman of Speracura LLC, a healthcare consulting company from 2009 and the President of the SDHB PHEOPARA Coalition from 2016.
Mr. Rothwell was formerly Chairman of Sanofi from February 2007 to October 2009 in the U.S. He also served as Chief Executive Officer and President of Sanofi-Aventis from September 2004 to February 2007. Mr. Rothwell oversaw all domestic commercial operations as well as the coordination of Industrial Affairs and Research and Development activities in the U.S. From May 2003 to September 2004, Mr. Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-Aventis U.S. in 2004. Prior to that, from January 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company’s Global Prescription Business. From January 1995 to January 1998, Mr. Rothwell also served as worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company’s Global Pharmaceutical Operations. In his long career, Mr. Rothwell has also served as Chief Executive Officer of Sandoz Pharmaceuticals, Vice President of Global Marketing and Sales at Burroughs Wellcome, and Senior Vice President of Marketing and Sales for the U.S. for Squibb Corporation which later became a Division of Bristol-Myers Squibb.
Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his J.D. from Seton Hall University.
He formerly served on the PhRMA Board of Directors, as well as the Institute of Medicine’s Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswoman’s Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey, as a Trustee of the Corporate Council for America’s Children at the Children’s Health Fund, the Board of Directors of Agenus (NASDAQ: AGEN), the Board of Directors of Akrimax Pharmaceuticals LLC, Chairman of the Board of Directors of Archimedes Pharma LLC , Chairman of the Board of Directors of New American Therapeutics, and a member of the Board of Visitors for Seton Hall Law school.
He also served as the Chairman of the Pheo Para Alliance from 2009 to 2014 which is a non-profit organization dedicated to helping patients who suffer from pheochromocytoma and paraganglioma.
John D. Harkey Jr., has been Director of the Company since April 2006. Mr. Harkey is Chairman and Chief Executive Officer of Consolidated Restaurant Operations, Inc. He currently serves on the Board of Directors, Audit Committee and Compensation Committee of Loral Space & Communications, Inc. (NASDAQ:LORL), and on the Board of Directors of Emisphere Technologies, Inc. (OTCBB:EMIS). Mr. Harkey is formerly the Chairman of the Board of Regency Gas Partners, L.P. (NYSE:RGP) has served on the Board of Directors of Energy Transfer Equity, LP (NYSE:ETE) and Energy Transfer Partners, LP (NYSE:ETP). He formerly served on Board of Directors of Leap Wireless International, Inc. (NASDAQ:LEAP) which was acquired by AT&T. He is also co-founder and formerly Executive Chairman of the Board of AveXis, Inc. (NASDAQ:AVXS). He serves on the Board of Directors of the Baylor Health Care System Foundation, The University of Texas System Chancellor’s Council Executive Committee and is a member of the McCombs School of Business Advisory Board at the University of Texas at Austin. He serves on the President’s Development Council of Howard Payne University, the CEO Advisory Board of Dallas Arboretum and the Executive Board of Circle Ten Council of the Boy Scouts of America, and is a member of the Young Presidents’ Organization. Mr. Harkey obtained a B.B.A. in Honors Finance and, a J.D. from the University of Texas at Austin and a M.B.A. from Stanford University School of Business. Mr. Harkey’s entrepreneurial background, his qualification as a financial expert, and his business and leadership experiences in a range of different industries make him an asset to our Board of Directors.
Tim McInerney has been a Director of the Company since March 2012. Mr. McInerney is a principal at Two River and a Partner of Riverbank Capital Securities, Inc. From 1992 to March 2007, Mr. McInerney was a Managing Director of Paramount BioCapital, Inc. where he oversaw the overall distribution of Paramount's private equity product. Prior to 1992, Mr. McInerney was a research analyst focusing on the biotechnology industry at Ladenburg, Thalman & Co. Prior to that, Mr. McInerney held equity sales positions at Bear Stearns & Co. and Shearson Lehman Brothers, Inc. Mr. McInerney also worked in sales and marketing for Bristol-Myers Squibb. Mr. McInerney is currently Chairman of the Board of Directors of Insite Vision, Inc., (OTCBB: INSV), and is a member of the Board of Directors of ZIOPHARM, Inc., (NASDAQ: ZIOP), and Edgemont Pharmaceuticals, LLC. He formerly served on the Board of Directors of Manhattan Pharmaceuticals, Inc., (OTCBB: TGTX). Mr. McInerney received his B.S. in pharmacy from St. John's University at New York. He also completed a post-graduate residency at the New York University Medical Center in drug information systems. Mr. McInerney's knowledge of the pharmaceutical industry and capital markets, and affiliations with the financial community make him an asset to our Board of Directors.
Jacob Plotsker has been a director of the Company since March 2012. Mr. Plotsker is currently President of Cambridge Sage Group, LLC, a strategic consulting firm focused on the pharmaceutical industry. Mr. Plotsker was previously Head of Commercialization at ODH, Inc (an Otsuka Company). Prior to joining ODH in 2015 he served as Director of IUS Strategy and Life Cycle Management at Bayer HealthCare. From 2009 through 2012 he was Senior Director, Commercial Operations and Head of Marketing for Teva Pharmaceuticals Women’s Health Division. Prior to joining Teva, Mr. Plotsker was Senior Director, US and Global Marketing at Schering-Plough Corp (previously Organon BioSciences prior to being acquired by Schering-Plough Corp, which was subsequently acquired by Merck & Co., Inc) where he was responsible for commercialization of marketed brands and launch strategy for brands in development. From 1990 to 2006, Mr. Plotsker served in various Finance and Marketing roles at Pfizer, Inc. including Director/Team Leader of the company’s Antifungal Franchise. From 1989 to 1990, Mr. Plotsker was an Accountant at Deloitte & Touche. Mr. Plotsker holds a Bachelor of Arts degree in Accounting & Information Systems from Queens College of the City University of New York, a Master of Business Administration in Marketing and Finance from New York University—Stern School of Business, and completed the Executive Development Program in General Management at the University of Chicago—Booth School of Business. From 2008 to 2014 Mr. Plotsker served on the Board of Directors of Sharsheret, a nonprofit 501©(3) organization providing support and resources to young women living with breast cancer, and served as President from 2009 through 2012. Mr. Plotsker’s experiences in marketing, and product commercialization in the pharmaceutical industry, and his affiliations with industry and healthcare related organizations make him an asset to our Board of Directors.
Mark H. Rachesky, M.D., has been a director of the Company since 2005. Dr. Rachesky is the founder and President of MHR Fund Management LLC, an investment manager of various private investment funds that invest in inefficient market sectors, including special situation equities. Dr. Rachesky is currently the Non-Executive Chairman of the Board of Directors of Loral Space & Communications Inc. (NASDAQ:LORL), Lions Gate Entertainment Corp. (NYSE: LGF), and Telesat Canada. He also serves on the Board of Directors of Navistar International Corporation (NYSE: NAV) and Titan International, Inc. (NYSE: TWI). Dr. Rachesky is a graduate of Stanford University School of Medicine and Stanford University School of Business. Dr. Rachesky graduated from the University of Pennsylvania with a major in Molecular Aspects of Cancer. Dr. Rachesky’s extensive investing and financial background, his thorough knowledge of capital markets and his training as an M.D., make him an asset to our Board of Directors.
Alan L. Rubino joined Emisphere in 2012 as President and Chief Executive Officer. Upon joining, he was also appointed as Class II Director of the Company. Mr. Rubino’s career spans over 30 years at every level of the biopharmaceutical industry.
Previously, he was President and CEO of New American Therapeutics Inc., a private specialty pharmaceutical company that acquired, marketed and developed therapeutic products and achieved major success through the acquisition, marketing, and eventual sale of its herpes labialis drug, Denavir® where the team tripled sales in 18 months and sold then sold the asset to Renaissance Pharmaceuticals, for a multiple of three times sales. Mr. Rubino served before New American Therapeutics, Inc. as the CEO and President of Akrimax Pharmaceuticals, where he and team acquired Tirosint® and NitroMist®, two key NDA approved launch products. Rounding out his background, he had also been President and COO of another publicly-held entity, Pharmos Corporation, where he led the transformation of the company through the acquisition of Vela Pharmaceuticals. Mr. Rubino also spent four years in senior leadership positions on the strategic services side of the healthcare sector with two other public companies, Cardinal Health and PDI Inc.
A major portion of Mr. Rubino’s highly successful career includes his twenty-four years spent at Hoffmann-La Roche, now Genentech (a subsidiary of Roche) which remains one of the world’s top 10 biopharmaceutical companies. At Roche, he was a corporate officer and member of the U.S. Executive Committee. He held a variety of key senior executive positions that encompassed business operations, business strategy, human resources, marketing, sales, corporate development and strategic planning.
Mr. Rubino currently serves on the Corporate Boards of Aastrom Biosciences, Genisphere, Inc. and Sanuwave Health, Inc. For the past 17 years, he has served on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. Mr. Rubino holds a B.A. in economics from Rutgers University along with a full minor in biology and chemistry. He also attended multiple executive education courses at Harvard Business School and the University of Lausanne in Switzerland.
Michael Weiser M.D., Ph.D. has been a director of the company since 2005.
Dr. Weiser is currently founder and co-chairman of Actin Biomed, a New York-based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs.
Prior to founding Actin Biomed in December 2006, Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development.
Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine. He performed his post-graduate medical training in the Department of Obstetrics and Gynecology at New York University Medical Center. Dr. Weiser also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and received his B.A. in Psychology from University of Vermont.
Dr. Weiser is a member of The National Medical Honor Society, Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology and Association for Research in Vision and Ophthalmology. In addition, Dr. Weiser has received awards for both academic and professional excellence and is published extensively in both medical and scientific journals.
Dr. Weiser also currently serves on the board of directors for Ziopharm Oncology, Inc., (NASDAQ: ZIOP), as well as several privately held companies.
Dr. Weiser previously served as a director of Chelsea Therapeutics International, (NASDAQ: CHTP), Hana Biosciences, Inc., (currently known as Talon Therapeutics, Inc., OTCBB: TLON.OB), Manhattan Pharmaceuticals, Inc., (OTCBB: TGTX), and Vioquest Pharmaceuticals, Inc., (VOQP: OTC US).
Dr. Weiser has an M.D. and a Ph.D., his scientific, business and financial experiences, as well as his knowledge of the healthcare industry, capital markets, pharmaceutical products and biomedical technology development make him an asset to our Board of Directors.